Back to Search Start Over

Inhibition of Wnt-β-Catenin Signaling by ICRT14 Drug Depends of Post-Transcriptional Regulation by HOTAIR in Human Cervical Cancer HeLa Cells.

Authors :
Trujano-Camacho S
Cantú-de León D
Delgado-Waldo I
Coronel-Hernández J
Millan-Catalan O
Hernández-Sotelo D
López-Camarillo C
Pérez-Plasencia C
Campos-Parra AD
Source :
Frontiers in oncology [Front Oncol] 2021 Oct 28; Vol. 11, pp. 729228. Date of Electronic Publication: 2021 Oct 28 (Print Publication: 2021).
Publication Year :
2021

Abstract

Background: In Cervical cancer (CC), in addition to HPV infection, the most relevant alteration during CC initiation and progression is the aberrant activation of Wnt/β-catenin pathway. Several inhibitory drugs of this pathway are undergoing preclinical and clinical studies. Long non-coding RNAs (lncRNAs) are associated with resistance to treatments. In this regard, understanding the efficiency of drugs that block the Wnt/β-catenin pathway in CC is of relevance to eventually propose successful target therapies in patients with this disease.<br />Methods: We analyzed the levels of expression of 249 components of the Wnt/β-catenin pathway in a group of 109 CC patients. Three drugs that blocking specific elements of Wnt/β-catenin pathway (C59, NSC668036 and ICRT14) by TOP FLASH assays and qRT-PCR were tested in vitro in CC cells.<br />Results: 137 genes of the Wnt/β-catenin pathway were up-regulated and 112 down-regulated in CC patient's samples, demonstrating that this pathway is dysregulated. C59 was an efficient drug to inhibit Wnt/β-catenin pathway in CC cells. NSC668036, was not able to inhibit the transcriptional activity of the Wnt/β-catenin pathway. Strikingly, ICRT14 was neither able to inhibit this pathway in HeLa cells, due to HOTAIR interaction with β-catenin, maintaining the Wnt/β-catenin pathway activated.<br />Conclusions: These results demonstrate a mechanism by which HOTAIR evades the effect of ICRT14, a Wnt/β-catenin pathway inhibitory drug, in HeLa cell line. The emergence of these mechanisms reveals new scenarios in the design of target therapies used in cancer.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Trujano-Camacho, Cantú-de León, Delgado-Waldo, Coronel-Hernández, Millan-Catalan, Hernández-Sotelo, López-Camarillo, Pérez-Plasencia and Campos-Parra.)

Details

Language :
English
ISSN :
2234-943X
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
34778043
Full Text :
https://doi.org/10.3389/fonc.2021.729228